{"id":368,"date":"2026-04-12T17:53:02","date_gmt":"2026-04-12T17:53:02","guid":{"rendered":"https:\/\/nutra-supplements.com\/?p=368"},"modified":"2026-04-12T17:54:03","modified_gmt":"2026-04-12T17:54:03","slug":"macular-degeneration-prevention-supplements","status":"publish","type":"post","link":"https:\/\/nutra-supplements.com\/fr\/macular-degeneration-prevention-supplements\/","title":{"rendered":"Macular Degeneration Prevention: What the Science Says (2026)"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\r\n\r\n\r\n\r\n\r\n\r\nMacular Degeneration Prevention: What the Science Says (2026) | Nutra Supplements<\/title>\r\n<meta name=\"description\" content=\"A complete, evidence-based guide to preventing age-related macular degeneration with supplements. Covers AREDS2 research, risk factors, the 5 key nutrients and a practical prevention protocol for every age.\">\r\n<meta name=\"keywords\" content=\"macular degeneration prevention supplements, AMD prevention, AREDS2 supplements, lutein zeaxanthin AMD, age related macular degeneration diet, how to prevent macular degeneration naturally\">\r\n<meta name=\"robots\" content=\"index, follow\">\r\n<link rel=\"canonical\" href=\"https:\/\/nutra-supplements.com\/macular-degeneration-prevention-supplements\/\">\r\n\r\n<meta property=\"og:type\" content=\"article\">\r\n<meta property=\"og:title\" content=\"Macular Degeneration Prevention: What the Science Says (2026)\">\r\n<meta property=\"og:description\" content=\"AREDS2 research, risk factors, key nutrients and a practical prevention protocol. Everything the science says about protecting your macula.\">\r\n<meta property=\"og:url\" content=\"https:\/\/nutra-supplements.com\/macular-degeneration-prevention-supplements\/\">\r\n<meta property=\"og:site_name\" content=\"Nutra Supplements\">\r\n<meta property=\"article:published_time\" content=\"2026-04-12T00:00:00Z\">\r\n<meta property=\"article:section\" content=\"Vision Health\">\r\n\r\n<meta name=\"twitter:card\" content=\"summary_large_image\">\r\n<meta name=\"twitter:title\" content=\"Macular Degeneration Prevention: What the Science Says (2026)\">\r\n<meta name=\"twitter:description\" content=\"AREDS2, risk factors, key nutrients and a practical AMD prevention protocol.\">\r\n\r\n<script type=\"application\/ld+json\">\r\n{\r\n \"@context\": \"https:\/\/schema.org\",\r\n \"@type\": \"Article\",\r\n \"headline\": \"Macular Degeneration Prevention: What the Science Says (2026)\",\r\n \"description\": \"A complete evidence-based guide to AMD prevention covering AREDS2 research, risk factors, key protective nutrients and a practical supplementation protocol.\",\r\n \"author\": { \"@type\": \"Organization\", \"name\": \"Nutra Supplements\", \"url\": \"https:\/\/nutra-supplements.com\" },\r\n \"publisher\": { \"@type\": \"Organization\", \"name\": \"Nutra Supplements\", \"url\": \"https:\/\/nutra-supplements.com\" },\r\n \"datePublished\": \"2026-04-12\",\r\n \"dateModified\": \"2026-04-12\",\r\n \"mainEntityOfPage\": { \"@type\": \"WebPage\", \"@id\": \"https:\/\/nutra-supplements.com\/macular-degeneration-prevention-supplements\/\" },\r\n \"articleSection\": \"Vision Health\",\r\n \"keywords\": \"macular degeneration prevention, AMD supplements, AREDS2, lutein zeaxanthin, macular health\",\r\n \"wordCount\": \"3600\"\r\n}\r\n<\/script>\r\n\r\n<script type=\"application\/ld+json\">\r\n{\r\n \"@context\": \"https:\/\/schema.org\",\r\n \"@type\": \"FAQPage\",\r\n \"mainEntity\": [\r\n {\r\n \"@type\": \"Question\",\r\n \"name\": \"Can macular degeneration be prevented with supplements?\",\r\n \"acceptedAnswer\": { \"@type\": \"Answer\", \"text\": \"Supplements cannot guarantee prevention, but the AREDS2 study \u2014 the gold standard in eye nutrition research \u2014 demonstrated that lutein and zeaxanthin supplementation significantly reduced the risk of AMD progression in high-risk individuals. For people with no current AMD, the same nutrients build the macular pigment that acts as the eye's primary defence against the oxidative damage that drives AMD development.\" }\r\n },\r\n {\r\n \"@type\": \"Question\",\r\n \"name\": \"What is the AREDS2 formula?\",\r\n \"acceptedAnswer\": { \"@type\": \"Answer\", \"text\": \"The AREDS2 formula is the supplement combination tested in the Age-Related Eye Disease Study 2, conducted by the National Eye Institute. It contains lutein 10 mg, zeaxanthin 2 mg, vitamin C 500 mg, vitamin E 400 IU, zinc 80 mg, and copper 2 mg per day. This combination was shown to reduce the risk of intermediate AMD progressing to advanced AMD by up to 25% over 5 years.\" }\r\n },\r\n {\r\n \"@type\": \"Question\",\r\n \"name\": \"At what age should I start taking eye supplements for AMD prevention?\",\r\n \"acceptedAnswer\": { \"@type\": \"Answer\", \"text\": \"Macular pigment density begins declining in the 30s and 40s in most people. Starting lutein and zeaxanthin supplementation in your 30s or 40s \u2014 before any symptoms appear \u2014 provides the greatest long-term benefit. By the time AMD is diagnosed, significant structural damage has already occurred. Prevention is substantially more effective than slowing progression.\" }\r\n },\r\n {\r\n \"@type\": \"Question\",\r\n \"name\": \"What foods are best for macular degeneration prevention?\",\r\n \"acceptedAnswer\": { \"@type\": \"Answer\", \"text\": \"The foods with the highest lutein and zeaxanthin content \u2014 the primary protective nutrients \u2014 are dark leafy greens (kale, spinach, collard greens) and egg yolks (which have exceptionally high bioavailability). Fatty fish (salmon, sardines, mackerel) provide omega-3s for anti-inflammatory protection. Orange and yellow vegetables (sweet corn, orange peppers) provide zeaxanthin. However, reaching therapeutic doses from food alone is difficult, making supplementation important for most people.\" }\r\n }\r\n ]\r\n}\r\n<\/script>\r\n\r\n<link rel=\"preconnect\" href=\"https:\/\/fonts.googleapis.com\">\r\n<link rel=\"preconnect\" href=\"https:\/\/fonts.gstatic.com\" crossorigin>\r\n<link href=\"https:\/\/fonts.googleapis.com\/css2?family=Cormorant+Garamond:ital,wght@0,300;0,400;0,500;0,600;1,300;1,400;1,500&family=DM+Sans:wght@300;400;500&display=swap\" rel=\"stylesheet\">\r\n\r\n<style>\r\n:root {\r\n --cream: #FAF7F2;\r\n --cream-mid: #F2EDE3;\r\n --cream-dark: #E8DFD0;\r\n --bark: #8B6F47;\r\n --bark-light: #BFA27A;\r\n --bark-dark: #5C4527;\r\n --ink: #1E1A14;\r\n --ink-mid: #4A4035;\r\n --ink-light: #7A6E62;\r\n --sage: #7D9E8A;\r\n --sage-light: #C5D9CC;\r\n --gold: #C8973A;\r\n --gold-light: #E8C87A;\r\n --white: #FFFFFF;\r\n --font-display: 'Cormorant Garamond', Georgia, serif;\r\n --font-body: 'DM Sans', system-ui, sans-serif;\r\n --radius-sm: 4px; --radius-md: 8px; --radius-lg: 14px;\r\n --content-w: 760px; --max-w: 1120px;\r\n}\r\n*, *::before, *::after { box-sizing: border-box; margin: 0; padding: 0; }\r\nhtml { scroll-behavior: smooth; }\r\nbody { font-family: var(--font-body); background: var(--cream); color: var(--ink); line-height: 1.82; font-size: 17px; font-weight: 300; }\r\nimg { max-width: 100%; display: block; }\r\na { color: var(--bark); text-decoration: none; transition: color 0.2s; }\r\na:hover { color: var(--bark-dark); }\r\nh1,h2,h3,h4 { font-family: var(--font-display); line-height: 1.2; color: var(--ink); }\r\nh1 { font-size: clamp(2rem, 4vw, 3.3rem); font-weight: 400; letter-spacing: -0.02em; }\r\nh2 { font-size: clamp(1.5rem, 2.5vw, 2rem); font-weight: 400; margin: 3rem 0 1rem; }\r\nh3 { font-size: clamp(1.1rem, 1.8vw, 1.4rem); font-weight: 400; margin: 2rem 0 0.7rem; }\r\nh4 { font-size: 1.05rem; font-weight: 500; margin: 1.4rem 0 0.5rem; }\r\np { margin-bottom: 1.35rem; }\r\nstrong { font-weight: 500; color: var(--ink); }\r\n\r\n.container { max-width: var(--max-w); margin: 0 auto; padding: 0 1.5rem; }\r\n.content-wrap { max-width: var(--content-w); margin: 0 auto; }\r\n.progress-bar { background: var(--gold); height: 3px; position: fixed; top: 0; left: 0; z-index: 200; transition: width 0.1s; }\r\n\r\n\/* HEADER *\/\r\nheader.site-header { background: var(--cream); border-bottom: 1px solid var(--cream-dark); padding: 0.9rem 0; position: sticky; top: 3px; z-index: 100; }\r\n.header-inner { display: flex; align-items: center; justify-content: space-between; gap: 1.5rem; }\r\n.logo img { height: 46px; width: auto; }\r\n.nav-links { display: flex; gap: 1.8rem; list-style: none; }\r\n.nav-links a { font-size: 0.78rem; letter-spacing: 0.08em; text-transform: uppercase; color: var(--ink-mid); font-weight: 400; }\r\n.nav-links a:hover { color: var(--bark-dark); }\r\n.lang-switcher { display: flex; align-items: center; gap: 0.15rem; background: var(--cream-mid); border: 1px solid var(--cream-dark); border-radius: 6px; padding: 0.2rem; }\r\n.lang-btn { background: none; border: none; color: var(--ink-light); font-family: var(--font-body); font-size: 0.7rem; font-weight: 500; letter-spacing: 0.06em; text-transform: uppercase; cursor: pointer; padding: 0.32rem 0.6rem; border-radius: 4px; transition: color 0.18s, background 0.18s; }\r\n.lang-btn:hover { color: var(--bark-dark); background: var(--cream-dark); }\r\n.lang-btn.active { background: var(--ink); color: var(--cream); }\r\n\r\n\/* BREADCRUMB *\/\r\n.breadcrumb { padding: 0.9rem 0; background: var(--cream-mid); border-bottom: 1px solid var(--cream-dark); }\r\n.bc-list { display: flex; align-items: center; gap: 0.5rem; list-style: none; font-size: 0.78rem; color: var(--ink-light); flex-wrap: wrap; }\r\n.bc-list li::after { content: '\u203a'; margin-left: 0.5rem; }\r\n.bc-list li:last-child::after { display: none; }\r\n.bc-list a { color: var(--bark); }\r\n\r\n\/* ARTICLE HEADER *\/\r\n.art-header { padding: 3.5rem 0 2.5rem; border-bottom: 1px solid var(--cream-dark); text-align: center; }\r\n.art-tag { display: inline-flex; align-items: center; gap: 0.7rem; font-size: 0.7rem; letter-spacing: 0.2em; text-transform: uppercase; color: var(--gold); font-family: var(--font-body); font-weight: 400; margin-bottom: 1rem; }\r\n.art-tag::before, .art-tag::after { content: ''; display: block; width: 22px; height: 1px; background: var(--gold); }\r\n.art-header h1 { font-style: italic; margin-bottom: 1rem; max-width: 820px; margin-left: auto; margin-right: auto; }\r\n.art-meta { display: flex; align-items: center; justify-content: center; gap: 1.4rem; flex-wrap: wrap; font-size: 0.78rem; color: var(--ink-light); margin-top: 1.2rem; }\r\n.art-meta span { display: flex; align-items: center; gap: 0.35rem; }\r\n.meta-dot { width: 3px; height: 3px; border-radius: 50%; background: var(--cream-dark); }\r\n\r\n.art-body { padding: 3rem 0 4rem; }\r\n\r\n\/* DISCLOSURE *\/\r\n.disclosure { background: var(--cream-mid); border: 1px solid var(--cream-dark); border-radius: var(--radius-md); padding: 1rem 1.3rem; margin-bottom: 2rem; font-size: 0.78rem; color: var(--ink-light); display: flex; gap: 0.7rem; align-items: flex-start; line-height: 1.65; }\r\n.disclosure svg { width: 16px; height: 16px; color: var(--gold); flex-shrink: 0; margin-top: 1px; }\r\n\r\n\/* LEAD *\/\r\n.art-lead { font-size: 1.1rem; color: var(--ink-mid); border-left: 3px solid var(--sage); padding-left: 1.4rem; margin-bottom: 2rem; font-style: italic; line-height: 1.85; font-family: var(--font-display); }\r\n\r\n\/* TOC *\/\r\n.toc { background: var(--white); border: 1px solid var(--cream-dark); border-left: 3px solid var(--gold); border-radius: var(--radius-lg); padding: 1.6rem 1.8rem; margin-bottom: 2.8rem; }\r\n.toc-title { font-family: var(--font-display); font-size: 1.05rem; font-weight: 500; color: var(--ink); margin-bottom: 0.9rem; display: flex; align-items: center; gap: 0.6rem; }\r\n.toc-list { list-style: none; counter-reset: toc; }\r\n.toc-list li { counter-increment: toc; margin-bottom: 0.4rem; }\r\n.toc-list li a { font-size: 0.88rem; color: var(--ink-mid); display: flex; align-items: baseline; gap: 0.55rem; }\r\n.toc-list li a::before { content: counter(toc, decimal-leading-zero); font-family: var(--font-display); font-size: 0.82rem; color: var(--gold); font-weight: 400; flex-shrink: 0; }\r\n.toc-list li a:hover { color: var(--bark-dark); }\r\n.toc-sub { list-style: none; margin: 0.3rem 0 0.3rem 2rem; }\r\n.toc-sub li { margin-bottom: 0.2rem; }\r\n.toc-sub a { font-size: 0.82rem; color: var(--ink-light); }\r\n\r\n\/* AMD STAGES *\/\r\n.stages-timeline { margin: 2rem 0; position: relative; }\r\n.stages-timeline::before { content: ''; position: absolute; left: 24px; top: 0; bottom: 0; width: 2px; background: var(--cream-dark); }\r\n.stage-item { display: flex; gap: 1.5rem; margin-bottom: 1.5rem; position: relative; }\r\n.stage-dot { width: 50px; height: 50px; border-radius: 50%; display: flex; align-items: center; justify-content: center; flex-shrink: 0; font-family: var(--font-display); font-weight: 400; font-size: 1rem; position: relative; z-index: 1; }\r\n.stage-dot.early { background: var(--sage-light); color: #4e7d6a; }\r\n.stage-dot.inter { background: rgba(200,151,58,0.18); color: var(--gold); }\r\n.stage-dot.advanced { background: rgba(139,111,71,0.18); color: var(--bark-dark); }\r\n.stage-content { padding-top: 0.5rem; }\r\n.stage-content h4 { font-size: 1rem; margin: 0 0 0.3rem; }\r\n.stage-content p { font-size: 0.85rem; color: var(--ink-mid); margin: 0; line-height: 1.6; }\r\n.stage-tag { display: inline-block; font-size: 0.65rem; letter-spacing: 0.1em; text-transform: uppercase; padding: 0.2rem 0.55rem; border-radius: 10px; margin-bottom: 0.35rem; font-weight: 500; }\r\n.tag-green { background: #e6f4ed; color: #2e7d5e; }\r\n.tag-gold { background: rgba(200,151,58,0.12); color: var(--bark); }\r\n.tag-red { background: rgba(139,111,71,0.1); color: var(--bark-dark); }\r\n\r\n\/* RISK FACTOR GRID *\/\r\n.risk-grid { display: grid; grid-template-columns: repeat(3, 1fr); gap: 1rem; margin: 1.5rem 0; }\r\n.risk-card { background: var(--white); border: 1px solid var(--cream-dark); border-radius: var(--radius-md); padding: 1.2rem; }\r\n.risk-card .r-icon { width: 36px; height: 36px; border-radius: 50%; background: var(--cream-mid); display: flex; align-items: center; justify-content: center; margin-bottom: 0.7rem; }\r\n.risk-card .r-icon svg { width: 18px; height: 18px; color: var(--sage); }\r\n.risk-card strong { display: block; font-size: 0.88rem; margin-bottom: 0.25rem; }\r\n.risk-card p { font-size: 0.78rem; color: var(--ink-light); margin: 0; line-height: 1.55; }\r\n.risk-card.modifiable { border-top: 3px solid var(--sage); }\r\n.risk-card.fixed { border-top: 3px solid var(--cream-dark); }\r\n\r\n\/* AREDS2 BOX *\/\r\n.areds-box { background: var(--ink); border-radius: var(--radius-lg); padding: 2.2rem; margin: 2.5rem 0; position: relative; overflow: hidden; }\r\n.areds-box::before { content: 'AREDS2'; position: absolute; right: -10px; top: -20px; font-family: var(--font-display); font-size: 7rem; font-weight: 300; color: rgba(255,255,255,0.04); line-height: 1; user-select: none; }\r\n.areds-header { display: flex; align-items: flex-start; gap: 1.2rem; margin-bottom: 1.5rem; }\r\n.areds-badge { background: var(--gold); color: var(--ink); font-size: 0.65rem; letter-spacing: 0.12em; text-transform: uppercase; padding: 0.3rem 0.8rem; border-radius: var(--radius-sm); font-weight: 500; white-space: nowrap; margin-top: 0.25rem; }\r\n.areds-box h3 { color: var(--cream); font-style: italic; margin: 0; font-size: 1.4rem; }\r\n.areds-box p { color: var(--bark-light); font-size: 0.9rem; margin-bottom: 1.2rem; }\r\n.areds-formula { display: grid; grid-template-columns: repeat(3, 1fr); gap: 0.8rem; }\r\n.formula-item { background: rgba(250,247,242,0.06); border: 1px solid rgba(191,162,122,0.2); border-radius: var(--radius-md); padding: 1rem; text-align: center; }\r\n.formula-item strong { display: block; font-family: var(--font-display); font-size: 1.4rem; color: var(--gold-light); font-weight: 300; line-height: 1; margin-bottom: 0.2rem; }\r\n.formula-item span { font-size: 0.72rem; color: var(--bark-light); letter-spacing: 0.06em; }\r\n.areds-result { background: rgba(125,158,138,0.12); border: 1px solid rgba(125,158,138,0.25); border-radius: var(--radius-md); padding: 1rem 1.2rem; margin-top: 1.2rem; display: flex; align-items: center; gap: 0.8rem; }\r\n.areds-result svg { width: 20px; height: 20px; color: var(--sage); flex-shrink: 0; }\r\n.areds-result p { color: rgba(250,247,242,0.8); font-size: 0.88rem; margin: 0; }\r\n.areds-result strong { color: var(--sage-light); }\r\n\r\n\/* CALLOUT *\/\r\n.callout { background: var(--white); border: 1px solid var(--cream-dark); border-radius: var(--radius-lg); padding: 1.4rem 1.7rem; margin: 2rem 0; display: flex; gap: 1.1rem; align-items: flex-start; }\r\n.callout-gold { border-left: 4px solid var(--gold); }\r\n.callout-sage { border-left: 4px solid var(--sage); }\r\n.callout-icon { width: 36px; height: 36px; flex-shrink: 0; border-radius: 50%; display: flex; align-items: center; justify-content: center; }\r\n.callout-gold .callout-icon { background: rgba(200,151,58,0.1); }\r\n.callout-sage .callout-icon { background: rgba(125,158,138,0.1); }\r\n.callout-icon svg { width: 18px; height: 18px; }\r\n.callout-gold .callout-icon svg { color: var(--gold); }\r\n.callout-sage .callout-icon svg { color: var(--sage); }\r\n.callout-body p { font-size: 0.9rem; margin-bottom: 0; color: var(--ink-mid); line-height: 1.75; }\r\n.callout-body strong { display: block; margin-bottom: 0.3rem; font-size: 0.93rem; color: var(--ink); }\r\n\r\n\/* NUTRIENT TABLE *\/\r\n.nut-table-wrap { overflow-x: auto; margin: 1.5rem 0; border-radius: var(--radius-lg); border: 1px solid var(--cream-dark); }\r\n.nut-table { width: 100%; border-collapse: collapse; font-size: 0.87rem; min-width: 520px; }\r\n.nut-table thead { background: var(--ink); }\r\n.nut-table th { padding: 0.8rem 1rem; text-align: left; font-size: 0.68rem; letter-spacing: 0.1em; text-transform: uppercase; color: var(--cream); font-weight: 400; }\r\n.nut-table td { padding: 0.8rem 1rem; border-bottom: 1px solid var(--cream-dark); color: var(--ink-mid); }\r\n.nut-table tr:last-child td { border-bottom: none; }\r\n.nut-table tr:nth-child(even) { background: var(--cream-mid); }\r\n.nut-table td:first-child { font-weight: 500; color: var(--ink); font-family: var(--font-display); font-size: 1rem; }\r\n.ev-high { color: #2e7d5e; font-weight: 500; font-size: 0.82rem; }\r\n.ev-med { color: var(--gold); font-weight: 500; font-size: 0.82rem; }\r\n\r\n\/* FOOD SOURCES TABLE *\/\r\n.food-grid { display: grid; grid-template-columns: 1fr 1fr; gap: 1rem; margin: 1.5rem 0; }\r\n.food-card { background: var(--white); border: 1px solid var(--cream-dark); border-radius: var(--radius-md); padding: 1.2rem; }\r\n.food-card h4 { font-size: 0.78rem; letter-spacing: 0.12em; text-transform: uppercase; color: var(--gold); margin-bottom: 0.7rem; }\r\n.food-card ul { list-style: none; padding: 0; }\r\n.food-card li { font-size: 0.85rem; color: var(--ink-mid); padding: 0.3rem 0 0.3rem 1.3rem; border-bottom: 1px solid var(--cream-mid); position: relative; }\r\n.food-card li:last-child { border-bottom: none; }\r\n.food-card li::before { content: ''; position: absolute; left: 0; top: 50%; transform: translateY(-50%); width: 5px; height: 5px; background: var(--sage); border-radius: 50%; }\r\n.food-card li span { color: var(--ink-light); font-size: 0.78rem; float: right; }\r\n\r\n\/* SECTION DIVIDER *\/\r\n.sec-divider { display: flex; align-items: center; gap: 1rem; margin: 3rem 0 2rem; }\r\n.sec-divider span { font-size: 0.68rem; letter-spacing: 0.2em; text-transform: uppercase; color: var(--gold); font-family: var(--font-body); white-space: nowrap; }\r\n.sec-divider::before, .sec-divider::after { content: ''; flex: 1; height: 1px; background: var(--cream-dark); }\r\n\r\n\/* PROTOCOL TABLE *\/\r\n.protocol-wrap { overflow-x: auto; margin: 1.5rem 0; border-radius: var(--radius-lg); border: 1px solid var(--cream-dark); }\r\n.protocol-table { width: 100%; border-collapse: collapse; font-size: 0.86rem; min-width: 480px; }\r\n.protocol-table thead { background: var(--ink); }\r\n.protocol-table th { padding: 0.8rem 1rem; text-align: left; font-size: 0.68rem; letter-spacing: 0.1em; text-transform: uppercase; color: var(--cream); font-weight: 400; }\r\n.protocol-table td { padding: 0.85rem 1rem; border-bottom: 1px solid var(--cream-dark); color: var(--ink-mid); vertical-align: middle; }\r\n.protocol-table tr:last-child td { border-bottom: none; }\r\n.protocol-table tr:nth-child(even) { background: var(--cream-mid); }\r\n.protocol-table td:first-child { font-weight: 500; color: var(--ink); font-family: var(--font-display); font-size: 0.98rem; }\r\n\r\n\/* MID CTA *\/\r\n.mid-cta { background: var(--cream-mid); border: 1px solid var(--cream-dark); border-radius: var(--radius-lg); padding: 1.8rem 2rem; margin: 2.5rem 0; display: flex; align-items: center; justify-content: space-between; gap: 1.5rem; flex-wrap: wrap; }\r\n.mid-cta-text strong { display: block; font-family: var(--font-display); font-size: 1.2rem; color: var(--ink); margin-bottom: 0.25rem; }\r\n.mid-cta-text p { font-size: 0.86rem; color: var(--ink-light); margin: 0; }\r\n.btn-mid { display: inline-flex; align-items: center; gap: 0.5rem; background: var(--ink); color: var(--cream); padding: 0.82rem 1.7rem; border-radius: var(--radius-sm); font-size: 0.75rem; letter-spacing: 0.11em; text-transform: uppercase; font-weight: 500; white-space: nowrap; transition: background 0.2s; }\r\n.btn-mid:hover { background: var(--bark-dark); color: var(--cream); }\r\n\r\n\/* FINAL CTA *\/\r\n.final-cta { background: var(--ink); border-radius: var(--radius-lg); padding: 2.5rem 2rem; margin: 3rem 0; text-align: center; position: relative; overflow: hidden; }\r\n.final-cta::before { content: ''; position: absolute; top: -50%; left: 50%; transform: translateX(-50%); width: 400px; height: 400px; background: radial-gradient(circle, rgba(200,151,58,0.07) 0%, transparent 70%); pointer-events: none; }\r\n.final-cta h2 { color: var(--cream); font-style: italic; margin-top: 0; margin-bottom: 0.7rem; font-size: 1.7rem; position: relative; z-index: 1; }\r\n.final-cta p { color: var(--bark-light); font-size: 0.9rem; max-width: 460px; margin: 0 auto 1.8rem; position: relative; z-index: 1; }\r\n.cta-btn-row { display: flex; gap: 0.8rem; justify-content: center; flex-wrap: wrap; position: relative; z-index: 1; }\r\n.btn-gold { display: inline-flex; align-items: center; gap: 0.5rem; background: var(--gold); color: var(--ink); padding: 0.88rem 2rem; border-radius: var(--radius-sm); font-size: 0.76rem; letter-spacing: 0.12em; text-transform: uppercase; font-weight: 500; transition: background 0.2s, transform 0.2s; }\r\n.btn-gold:hover { background: var(--gold-light); color: var(--ink); transform: translateY(-1px); }\r\n.btn-ghost-light { display: inline-flex; align-items: center; gap: 0.5rem; border: 1px solid rgba(191,162,122,0.4); color: var(--bark-light); padding: 0.88rem 2rem; border-radius: var(--radius-sm); font-size: 0.76rem; letter-spacing: 0.12em; text-transform: uppercase; font-weight: 400; transition: border-color 0.2s, color 0.2s; }\r\n.btn-ghost-light:hover { border-color: var(--bark-light); color: var(--cream); }\r\n\r\n\/* FAQ *\/\r\n.faq-item { border-bottom: 1px solid var(--cream-dark); padding: 1.1rem 0; }\r\n.faq-item:last-child { border-bottom: none; }\r\n.faq-q { font-family: var(--font-display); font-size: 1.08rem; font-weight: 500; color: var(--ink); cursor: pointer; display: flex; justify-content: space-between; align-items: flex-start; gap: 1rem; user-select: none; }\r\n.faq-q svg { width: 18px; height: 18px; color: var(--gold); flex-shrink: 0; margin-top: 3px; transition: transform 0.3s; }\r\n.faq-q.open svg { transform: rotate(45deg); }\r\n.faq-a { font-size: 0.91rem; color: var(--ink-light); line-height: 1.8; display: none; padding-top: 0.8rem; }\r\n.faq-a.visible { display: block; }\r\n\r\n\/* SHARE *\/\r\n.share-bar { display: flex; align-items: center; gap: 0.8rem; flex-wrap: wrap; padding: 1.4rem 0; border-top: 1px solid var(--cream-dark); border-bottom: 1px solid var(--cream-dark); margin: 2.5rem 0; }\r\n.share-label { font-size: 0.72rem; letter-spacing: 0.1em; text-transform: uppercase; color: var(--ink-light); }\r\n.share-btn { display: inline-flex; align-items: center; gap: 0.4rem; border: 1px solid var(--cream-dark); border-radius: 20px; padding: 0.32rem 0.9rem; font-size: 0.74rem; color: var(--ink-mid); background: var(--white); font-family: var(--font-body); cursor: pointer; transition: border-color 0.2s, color 0.2s; }\r\n.share-btn:hover { border-color: var(--bark-light); color: var(--bark-dark); }\r\n\r\n\/* RELATED *\/\r\n.related-grid { display: grid; grid-template-columns: 1fr 1fr; gap: 1.2rem; margin-top: 1.4rem; }\r\n.related-card { background: var(--white); border: 1px solid var(--cream-dark); border-radius: var(--radius-lg); padding: 1.2rem 1.4rem; transition: transform 0.2s, box-shadow 0.2s; }\r\n.related-card:hover { transform: translateY(-3px); box-shadow: 0 8px 24px rgba(92,69,39,0.08); }\r\n.related-type { font-size: 0.64rem; letter-spacing: 0.14em; text-transform: uppercase; color: var(--gold); margin-bottom: 0.35rem; display: block; }\r\n.related-title { font-family: var(--font-display); font-size: 1rem; color: var(--ink); line-height: 1.3; }\r\n\r\n\/* FOOTER *\/\r\nfooter { background: var(--ink); border-top: 1px solid rgba(191,162,122,0.15); padding: 2rem 0; text-align: center; }\r\n.footer-disclaimer { font-size: 0.77rem; color: var(--ink-light); max-width: 700px; margin: 0 auto 1.2rem; line-height: 1.7; }\r\n.footer-links { display: flex; justify-content: center; gap: 1.5rem; flex-wrap: wrap; margin-bottom: 1rem; }\r\n.footer-links a { font-size: 0.77rem; color: var(--bark-light); }\r\n.footer-links a:hover { color: var(--gold-light); }\r\n.footer-copy { font-size: 0.74rem; color: var(--ink-light); }\r\n\r\n@media (max-width: 720px) {\r\n .risk-grid { grid-template-columns: repeat(2, 1fr); }\r\n .areds-formula { grid-template-columns: repeat(2, 1fr); }\r\n .food-grid { grid-template-columns: 1fr; }\r\n .mid-cta { flex-direction: column; text-align: center; }\r\n .related-grid { grid-template-columns: 1fr; }\r\n .cta-btn-row { flex-direction: column; align-items: center; }\r\n .nav-links { display: none; }\r\n .stages-timeline::before { display: none; }\r\n}\r\n@media (max-width: 480px) {\r\n .risk-grid { grid-template-columns: 1fr; }\r\n .areds-formula { grid-template-columns: 1fr; }\r\n}\r\n<\/style>\r\n<\/head>\r\n<body>\r\n\r\n<div class=\"progress-bar\" id=\"progress\"><\/div>\r\n\r\n<!-- HEADER -->\r\n<header class=\"site-header\">\r\n <div class=\"container\">\r\n <div class=\"header-inner\">\r\n <a href=\"\/\" class=\"logo\">\r\n <img decoding=\"async\" src=\"\/images\/logonutrasupplements-180x70.jpg\" alt=\"Nutra Supplements\">\r\n <\/a>\r\n <ul class=\"nav-links\">\r\n <li><a href=\"\/category\/vision-health\/\">Vision Health<\/a><\/li>\r\n <li><a href=\"\/vision-health-supplements-guide\/\">Complete Guide<\/a><\/li>\r\n <li><a href=\"\/\">Home<\/a><\/li>\r\n <\/ul>\r\n <div class=\"lang-switcher\">\r\n <button class=\"lang-btn active\">EN<\/button>\r\n <button class=\"lang-btn\">ES<\/button>\r\n <button class=\"lang-btn\">DE<\/button>\r\n <button class=\"lang-btn\">FR<\/button>\r\n <button class=\"lang-btn\">IT<\/button>\r\n <\/div>\r\n <\/div>\r\n <\/div>\r\n<\/header>\r\n\r\n<!-- BREADCRUMB -->\r\n<nav class=\"breadcrumb\" aria-label=\"Breadcrumb\">\r\n <div class=\"container\">\r\n <ol class=\"bc-list\">\r\n <li><a href=\"\/\">Home<\/a><\/li>\r\n <li><a href=\"\/category\/vision-health\/\">Vision Health<\/a><\/li>\r\n <li aria-current=\"page\">Macular Degeneration Prevention: What the Science Says<\/li>\r\n <\/ol>\r\n <\/div>\r\n<\/nav>\r\n\r\n<!-- ARTICLE HEADER -->\r\n<header class=\"art-header\">\r\n <div class=\"container\">\r\n <div class=\"content-wrap\" style=\"max-width:840px;\">\r\n <div class=\"art-tag\">Science Guide \u00b7 Vision Health<\/div>\r\n <h1>Macular Degeneration Prevention: <em>What the Science Says<\/em> (2026)<\/h1>\r\n <div class=\"art-meta\">\r\n <span>\r\n <svg width=\"14\" height=\"14\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"1.5\"><rect x=\"3\" y=\"4\" width=\"18\" height=\"18\" rx=\"2\"\/><path d=\"M16 2v4M8 2v4M3 10h18\"\/><\/svg>\r\n April 12, 2026\r\n <\/span>\r\n <span class=\"meta-dot\"><\/span>\r\n <span>\r\n <svg width=\"14\" height=\"14\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"1.5\"><path d=\"M12 6v6l4 2\"\/><circle cx=\"12\" cy=\"12\" r=\"9\"\/><\/svg>\r\n 12 min read\r\n <\/span>\r\n <span class=\"meta-dot\"><\/span>\r\n <span>\r\n <svg width=\"14\" height=\"14\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"1.5\"><path d=\"M9 12.75L11.25 15 15 9.75M21 12a9 9 0 11-18 0 9 9 0 0118 0z\"\/><\/svg>\r\n AREDS2 \u00b7 Peer-reviewed \u00b7 ~3,600 words\r\n <\/span>\r\n <\/div>\r\n <\/div>\r\n <\/div>\r\n<\/header>\r\n\r\n<!-- BODY -->\r\n<main class=\"art-body\">\r\n <div class=\"container\">\r\n <div class=\"content-wrap\">\r\n\r\n <!-- DISCLOSURE -->\r\n <div class=\"disclosure\">\r\n <svg viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"1.5\"><circle cx=\"12\" cy=\"12\" r=\"9\"\/><path d=\"M12 8v4m0 4h.01\"\/><\/svg>\r\n <span><strong>Affiliate Disclosure:<\/strong> This article contains affiliate links. We may earn a commission from qualifying purchases at no extra cost to you. All content is independent and based solely on clinical evidence.<\/span>\r\n <\/div>\r\n\r\n <!-- LEAD -->\r\n <p class=\"art-lead\">\r\n Age-related macular degeneration is the leading cause of irreversible vision loss in adults over 50 in the developed world. There is no cure. But there is compelling, peer-reviewed evidence that targeted nutrition can dramatically reduce your risk of developing it \u2014 and slow its progression if it has already begun. Here is what the science actually says.\r\n <\/p>\r\n\r\n <!-- TOC -->\r\n <nav class=\"toc\" aria-label=\"Table of contents\">\r\n <div class=\"toc-title\">\r\n <svg width=\"17\" height=\"17\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"#C8973A\" stroke-width=\"1.5\"><path d=\"M8.25 6.75h7.5M8.25 12h7.5M8.25 17.25h7.5\"\/><\/svg>\r\n In This Guide\r\n <\/div>\r\n <ol class=\"toc-list\">\r\n <li><a href=\"#what-is-amd\">What Is Macular Degeneration?<\/a><\/li>\r\n <li><a href=\"#stages\">The Three Stages of AMD<\/a><\/li>\r\n <li><a href=\"#risk-factors\">Risk Factors \u2014 What You Can and Cannot Control<\/a><\/li>\r\n <li><a href=\"#areds2\">The AREDS2 Study \u2014 The Gold Standard Evidence<\/a><\/li>\r\n <li><a href=\"#nutrients\">The 5 Key Protective Nutrients<\/a><\/li>\r\n <li><a href=\"#food-sources\">Best Food Sources<\/a><\/li>\r\n <li><a href=\"#protocol\">Prevention Protocol by Age Group<\/a><\/li>\r\n <li><a href=\"#faq\">Frequently Asked Questions<\/a><\/li>\r\n <\/ol>\r\n <\/nav>\r\n\r\n <!-- SECTION 1: WHAT IS AMD -->\r\n <section id=\"what-is-amd\">\r\n <h2>What Is Macular Degeneration?<\/h2>\r\n <p>The macula is a small, highly specialised region at the centre of the retina \u2014 approximately 5.5 mm in diameter \u2014 responsible for the sharp, central vision required for reading, driving, recognising faces, and seeing fine detail. It contains the highest concentration of photoreceptor cone cells in the eye, and it is the part of the retina most vulnerable to age-related deterioration.<\/p>\r\n <p><strong>Age-related macular degeneration (AMD)<\/strong> is the progressive breakdown of the macular tissue driven by a combination of cumulative oxidative damage, chronic inflammation, genetic susceptibility and nutritional deficiency. As macular cells deteriorate, the sharp central vision they provide deteriorates with them \u2014 while peripheral vision typically remains intact.<\/p>\r\n <p>AMD affects approximately 196 million people worldwide and is the leading cause of legal blindness in adults over 50 in high-income countries. In the United States alone, 11 million people have some form of AMD \u2014 a number projected to double by 2050 as the population ages.<\/p>\r\n <p>There are two forms: <strong>dry AMD<\/strong> (atrophic) \u2014 accounting for 85\u201390% of cases \u2014 characterised by the gradual accumulation of drusen (protein and lipid deposits) beneath the retina and the progressive atrophy of macular cells; and <strong>wet AMD<\/strong> (neovascular) \u2014 accounting for 10\u201315% of cases but responsible for the majority of severe vision loss \u2014 characterised by the growth of abnormal, leaking blood vessels beneath the retina.<\/p>\r\n <\/section>\r\n\r\n <!-- SECTION 2: STAGES -->\r\n <section id=\"stages\">\r\n <h2>The Three Stages of AMD<\/h2>\r\n <p>AMD progresses through three defined stages. Understanding your current stage determines which intervention is appropriate.<\/p>\r\n\r\n <div class=\"stages-timeline\">\r\n <div class=\"stage-item\">\r\n <div class=\"stage-dot early\">E<\/div>\r\n <div class=\"stage-content\">\r\n <span class=\"stage-tag tag-green\">Early AMD<\/span>\r\n <h4>Early AMD \u2014 Often No Symptoms<\/h4>\r\n <p>Characterised by medium-sized drusen (yellowish deposits) beneath the retina. Vision is typically unaffected. Detectable only through dilated eye examination or OCT imaging. Most people at this stage are unaware they have any problem. <strong>Intervention here has the greatest long-term impact.<\/strong><\/p>\r\n <\/div>\r\n <\/div>\r\n <div class=\"stage-item\">\r\n <div class=\"stage-dot inter\">I<\/div>\r\n <div class=\"stage-content\">\r\n <span class=\"stage-tag tag-gold\">Intermediate AMD<\/span>\r\n <h4>Intermediate AMD \u2014 Mild Symptoms Possible<\/h4>\r\n <p>Large drusen present, sometimes with changes in the retinal pigment epithelium. Mild central vision blurring or difficulty in low light may occur. This is the stage at which the AREDS2 formula has its strongest documented protective effect \u2014 reducing risk of progression to advanced AMD by up to 25% over 5 years.<\/p>\r\n <\/div>\r\n <\/div>\r\n <div class=\"stage-item\">\r\n <div class=\"stage-dot advanced\">A<\/div>\r\n <div class=\"stage-content\">\r\n <span class=\"stage-tag tag-red\">Advanced AMD<\/span>\r\n <h4>Advanced AMD \u2014 Significant Vision Loss<\/h4>\r\n <p>Either geographic atrophy (large areas of RPE and photoreceptor cell death) or neovascular\/wet AMD (abnormal blood vessel growth, leakage, scarring). Central vision loss is substantial and often irreversible. Medical treatment (anti-VEGF injections for wet AMD) may slow progression but cannot restore lost vision.<\/p>\r\n <\/div>\r\n <\/div>\r\n <\/div>\r\n\r\n <div class=\"callout callout-gold\">\r\n <div class=\"callout-icon\">\r\n <svg viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"1.5\"><path d=\"M12 9v3.75m-9.303 3.376c-.866 1.5.217 3.374 1.948 3.374h14.71c1.73 0 2.813-1.874 1.948-3.374L13.949 3.378c-.866-1.5-3.032-1.5-3.898 0L2.697 16.126zM12 15.75h.007v.008H12v-.008z\"\/><\/svg>\r\n <\/div>\r\n <div class=\"callout-body\">\r\n <strong>The Critical Window<\/strong>\r\n <p>Prevention is dramatically more effective than treatment at every stage. By the time vision loss is noticeable, significant and irreversible structural damage has already occurred. The ideal time to begin a protective supplement protocol is in your 30s or 40s \u2014 well before any symptoms appear \u2014 when the macular pigment is still dense and the photoreceptors are intact.<\/p>\r\n <\/div>\r\n <\/div>\r\n <\/section>\r\n\r\n <!-- SECTION 3: RISK FACTORS -->\r\n <section id=\"risk-factors\">\r\n <h2>Risk Factors \u2014 What You Can and Cannot Control<\/h2>\r\n <p>AMD risk is determined by a combination of modifiable lifestyle factors and fixed biological characteristics. Understanding which category your risk falls into clarifies how aggressively to approach prevention.<\/p>\r\n\r\n <div class=\"risk-grid\">\r\n <div class=\"risk-card modifiable\">\r\n <div class=\"r-icon\"><svg viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"1.5\"><path d=\"M15.362 5.214A8.252 8.252 0 0112 21 8.25 8.25 0 016.038 7.048 8.287 8.287 0 009 9.6a8.983 8.983 0 013.361-6.867 8.21 8.21 0 003 2.48z\"\/><\/svg><\/div>\r\n <strong>Smoking<\/strong>\r\n <p>The single largest modifiable risk factor \u2014 smokers have 2\u20134\u00d7 the AMD risk of non-smokers. Toxins in smoke deplete macular antioxidants and accelerate RPE degeneration.<\/p>\r\n <\/div>\r\n <div class=\"risk-card modifiable\">\r\n <div class=\"r-icon\"><svg viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"1.5\"><path d=\"M12 3v2.25m6.364.386l-1.591 1.591M21 12h-2.25m-.386 6.364l-1.591-1.591M12 18.75V21m-4.773-4.227l-1.591 1.591M5.25 12H3m4.227-4.773L5.636 5.636M15.75 12a3.75 3.75 0 11-7.5 0 3.75 3.75 0 017.5 0z\"\/><\/svg><\/div>\r\n <strong>Chronic UV & Blue Light Exposure<\/strong>\r\n <p>Unprotected long-term light exposure generates oxidative damage in the macula. Screen use, outdoor sun exposure and LED lighting are the primary modern sources.<\/p>\r\n <\/div>\r\n <div class=\"risk-card modifiable\">\r\n <div class=\"r-icon\"><svg viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"1.5\"><path d=\"M21 8.25c0-2.485-2.099-4.5-4.688-4.5-1.935 0-3.597 1.126-4.312 2.733-.715-1.607-2.377-2.733-4.313-2.733C5.1 3.75 3 5.765 3 8.25c0 7.22 9 12 9 12s9-4.78 9-12z\"\/><\/svg><\/div>\r\n <strong>Poor Diet<\/strong>\r\n <p>Low intake of lutein, zeaxanthin, omega-3s and antioxidant vitamins is independently associated with higher AMD risk. Dietary patterns matter as much as individual nutrients.<\/p>\r\n <\/div>\r\n <div class=\"risk-card modifiable\">\r\n <div class=\"r-icon\"><svg viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"1.5\"><path d=\"M3.75 13.5l10.5-11.25L12 10.5h8.25L9.75 21.75 12 13.5H3.75z\"\/><\/svg><\/div>\r\n <strong>Cardiovascular Disease<\/strong>\r\n <p>Hypertension, high cholesterol and atherosclerosis impair choroidal blood flow to the retina. Cardiovascular and AMD risk factors overlap substantially.<\/p>\r\n <\/div>\r\n <div class=\"risk-card fixed\">\r\n <div class=\"r-icon\"><svg viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"1.5\"><path d=\"M9.75 3.104v5.714a2.25 2.25 0 01-.659 1.591L5 14.5M9.75 3.104c-.251.023-.501.05-.75.082m.75-.082a24.301 24.301 0 014.5 0m0 0v5.714c0 .597.237 1.17.659 1.591L19.8 15.3M14.25 3.104c.251.023.501.05.75.082\"\/><\/svg><\/div>\r\n <strong>Genetics (CFH, ARMS2)<\/strong>\r\n <p>Variants in the CFH and ARMS2 genes are the strongest known genetic risk factors. Having both high-risk alleles increases lifetime AMD risk by 50\u201360%. AREDS2 benefits are especially significant in this group.<\/p>\r\n <\/div>\r\n <div class=\"risk-card fixed\">\r\n <div class=\"r-icon\"><svg viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"1.5\"><path d=\"M6.75 3v2.25M17.25 3v2.25M3 18.75V7.5a2.25 2.25 0 012.25-2.25h13.5A2.25 2.25 0 0121 7.5v11.25\"\/><\/svg><\/div>\r\n <strong>Age & Light Iris Colour<\/strong>\r\n <p>Risk increases exponentially after 50. Light-coloured eyes (blue, green, grey) transmit more blue light to the retina than darker irides, increasing cumulative photochemical damage.<\/p>\r\n <\/div>\r\n <\/div>\r\n <\/section>\r\n\r\n <!-- SECTION 4: AREDS2 -->\r\n <section id=\"areds2\">\r\n <h2>The AREDS2 Study \u2014 The Gold Standard Evidence<\/h2>\r\n <p>The Age-Related Eye Disease Study 2 (AREDS2), conducted by the National Eye Institute and published in <em>JAMA<\/em> in 2013 with long-term follow-up published through 2022, is the most important clinical trial ever conducted in nutritional eye health. Its findings directly underpin every serious eye supplement formulation available today.<\/p>\r\n\r\n <h3>Study Design<\/h3>\r\n <p>AREDS2 was a randomised, double-blind, placebo-controlled trial enrolling <strong>4,203 participants<\/strong> aged 50\u201385 with intermediate AMD or advanced AMD in one eye. The primary outcome was progression to advanced AMD over a median follow-up of <strong>5 years<\/strong>. It tested multiple nutritional combinations, including replacing beta-carotene with lutein\/zeaxanthin, and adding omega-3 fatty acids.<\/p>\r\n\r\n <div class=\"areds-box\">\r\n <div class=\"areds-header\">\r\n <span class=\"areds-badge\">AREDS2 Formula<\/span>\r\n <h3>The Validated Daily Combination<\/h3>\r\n <\/div>\r\n <p>The AREDS2 formula that demonstrated the strongest AMD risk reduction contains the following daily doses:<\/p>\r\n <div class=\"areds-formula\">\r\n <div class=\"formula-item\">\r\n <strong>10 mg<\/strong>\r\n <span>Lutein (FloraGLO\u00ae)<\/span>\r\n <\/div>\r\n <div class=\"formula-item\">\r\n <strong>2 mg<\/strong>\r\n <span>Zeaxanthin<\/span>\r\n <\/div>\r\n <div class=\"formula-item\">\r\n <strong>500 mg<\/strong>\r\n <span>Vitamin C<\/span>\r\n <\/div>\r\n <div class=\"formula-item\">\r\n <strong>400 IU<\/strong>\r\n <span>Vitamin E<\/span>\r\n <\/div>\r\n <div class=\"formula-item\">\r\n <strong>80 mg<\/strong>\r\n <span>Zinc (+ 2 mg copper)<\/span>\r\n <\/div>\r\n <div class=\"formula-item\">\r\n <strong>Daily<\/strong>\r\n <span>Consistent use required<\/span>\r\n <\/div>\r\n <\/div>\r\n <div class=\"areds-result\">\r\n <svg viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"1.5\"><path d=\"M9 12.75L11.25 15 15 9.75M21 12a9 9 0 11-18 0 9 9 0 0118 0z\"\/><\/svg>\r\n <p><strong>Key finding:<\/strong> Lutein\/zeaxanthin reduced the risk of progression to advanced AMD by <strong>up to 26%<\/strong> in participants with intermediate AMD. The 10-year follow-up (AREDS2 extension) confirmed continued benefit with sustained use.<\/p>\r\n <\/div>\r\n <\/div>\r\n\r\n <h3>Key Findings Beyond the Headline<\/h3>\r\n <p>Several additional findings from AREDS2 are clinically important for anyone designing a prevention protocol:<\/p>\r\n\r\n <p><strong>Lutein\/zeaxanthin outperformed beta-carotene<\/strong> \u2014 the original AREDS formula used beta-carotene as the carotenoid component. AREDS2 replaced it with lutein\/zeaxanthin, which proved more effective and avoided the lung cancer risk beta-carotene poses in smokers.<\/p>\r\n\r\n <p><strong>Omega-3 addition did not show benefit over the base formula<\/strong> in AREDS2 \u2014 but this finding has been contested, as the study was not powered to detect omega-3-specific effects. Multiple independent trials have since confirmed omega-3 benefits for dry eye and overall retinal health.<\/p>\r\n\r\n <p><strong>Genetic subgroup analysis<\/strong> showed that participants with the high-risk CFH and ARMS2 genetic variants benefited most dramatically from lutein\/zeaxanthin supplementation \u2014 a finding that has been validated in subsequent studies.<\/p>\r\n\r\n <div class=\"callout callout-sage\">\r\n <div class=\"callout-icon\">\r\n <svg viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"1.5\"><path d=\"M12 18v-5.25m0 0a6.01 6.01 0 001.5-.189m-1.5.189a6.01 6.01 0 01-1.5-.189m3.75 7.478a12.06 12.06 0 01-4.5 0m3.75 2.383a14.406 14.406 0 01-3 0M14.25 18v-.192c0-.983.658-1.823 1.508-2.316a7.5 7.5 0 10-7.517 0c.85.493 1.509 1.333 1.509 2.316V18\"\/><\/svg>\r\n <\/div>\r\n <div class=\"callout-body\">\r\n <strong>AREDS2 Was Designed for People With Existing AMD<\/strong>\r\n <p>An important nuance: the AREDS2 trial enrolled participants who already had intermediate to advanced AMD. Its 26% risk reduction finding applies to this population. For people with no current AMD \u2014 the majority of supplement users \u2014 the evidence base shifts to epidemiological studies and macular pigment research, which consistently show that higher lutein\/zeaxanthin intake is associated with significantly lower AMD incidence. Prevention and progression-slowing are distinct, but both are supported by the evidence.<\/p>\r\n <\/div>\r\n <\/div>\r\n <\/section>\r\n\r\n <!-- SECTION 5: NUTRIENTS -->\r\n <div class=\"sec-divider\"><span>The Protective Nutrients<\/span><\/div>\r\n <section id=\"nutrients\">\r\n <h2>The 5 Key Protective Nutrients<\/h2>\r\n <p>Beyond the AREDS2 core formula, a comprehensive AMD prevention protocol draws on five nutrients with converging evidence:<\/p>\r\n\r\n <div class=\"nut-table-wrap\">\r\n <table class=\"nut-table\">\r\n <thead>\r\n <tr>\r\n <th>Nutrient<\/th>\r\n <th>Primary Mechanism<\/th>\r\n <th>Evidence Level<\/th>\r\n <th>Key Trial \/ Source<\/th>\r\n <th>Daily Dose<\/th>\r\n <\/tr>\r\n <\/thead>\r\n <tbody>\r\n <tr>\r\n <td>Lutein<\/td>\r\n <td>Macular pigment \/ blue light filter \/ antioxidant<\/td>\r\n <td><span class=\"ev-high\">Very High<\/span><\/td>\r\n <td>AREDS2 (n=4,203)<\/td>\r\n <td>10 mg<\/td>\r\n <\/tr>\r\n <tr>\r\n <td>Zeaxanthin<\/td>\r\n <td>Central foveal protection \/ MPOD density<\/td>\r\n <td><span class=\"ev-high\">Very High<\/span><\/td>\r\n <td>AREDS2 + MPOD trials<\/td>\r\n <td>2 mg<\/td>\r\n <\/tr>\r\n <tr>\r\n <td>Omega-3 (EPA+DHA)<\/td>\r\n <td>Anti-inflammation \/ DHA retinal structure<\/td>\r\n <td><span class=\"ev-high\">High<\/span><\/td>\r\n <td>Multiple RCTs + meta-analyses<\/td>\r\n <td>1,000\u20132,000 mg<\/td>\r\n <\/tr>\r\n <tr>\r\n <td>Vitamins C & E<\/td>\r\n <td>Antioxidant defence in aqueous humour & membranes<\/td>\r\n <td><span class=\"ev-high\">High<\/span><\/td>\r\n <td>AREDS1 + AREDS2<\/td>\r\n <td>500 mg C \/ 400 IU E<\/td>\r\n <\/tr>\r\n <tr>\r\n <td>Zinc<\/td>\r\n <td>Cofactor for retinal antioxidant enzymes \/ vitamin A metabolism<\/td>\r\n <td><span class=\"ev-med\">Moderate\u2013High<\/span><\/td>\r\n <td>AREDS1 + AREDS2<\/td>\r\n <td>25\u201380 mg (+ 2 mg copper)<\/td>\r\n <\/tr>\r\n <\/tbody>\r\n <\/table>\r\n <\/div>\r\n\r\n <h3>The Emerging Additions<\/h3>\r\n <p>Beyond the AREDS2 core, two additional nutrients have accumulated meaningful evidence in AMD-specific research since 2020:<\/p>\r\n\r\n <h4>Saffron (Crocus sativus)<\/h4>\r\n <p>A series of Italian randomised controlled trials led by Professor Silvia Bisti found that saffron extract (20 mg\/day) significantly improved photoreceptor function \u2014 measured by electroretinogram (ERG) \u2014 in early AMD patients. The active compounds crocin and crocetin appear to have direct neuroprotective effects on retinal cells, independent of antioxidant pathways. While the evidence base is smaller than for AREDS2 nutrients, the mechanism is distinct and potentially additive.<\/p>\r\n\r\n <h4>Meso-Zeaxanthin<\/h4>\r\n <p>The triple carotenoid combination \u2014 adding meso-zeaxanthin to lutein and zeaxanthin \u2014 produces greater increases in central macular pigment density than the standard two-carotenoid approach. Research from the Macular Pigment Research Group at Waterford Institute of Technology found the 10:10:2 (lutein:meso-zeaxanthin:zeaxanthin) combination produced significantly higher MPOD in the central fovea \u2014 the region most critical for sharp vision and most vulnerable to AMD progression.<\/p>\r\n <\/section>\r\n\r\n <!-- SECTION 6: FOOD SOURCES -->\r\n <div class=\"sec-divider\"><span>Diet & Food<\/span><\/div>\r\n <section id=\"food-sources\">\r\n <h2>Best Food Sources for AMD Prevention<\/h2>\r\n <p>A Mediterranean-style dietary pattern \u2014 rich in vegetables, fish, olive oil and moderate in refined carbohydrates \u2014 is consistently associated with lower AMD risk in large epidemiological studies. Here are the specific foods with the highest concentrations of the key protective nutrients:<\/p>\r\n\r\n <div class=\"food-grid\">\r\n <div class=\"food-card\">\r\n <h4>Lutein & Zeaxanthin Sources<\/h4>\r\n <ul>\r\n <li>Kale (cooked) <span>22 mg \/ 100g<\/span><\/li>\r\n <li>Spinach (cooked) <span>12 mg \/ 100g<\/span><\/li>\r\n <li>Collard greens <span>16 mg \/ 100g<\/span><\/li>\r\n <li>Egg yolks <span>~0.3 mg \/ yolk*<\/span><\/li>\r\n <li>Sweet corn <span>1.8 mg \/ 100g<\/span><\/li>\r\n <li>Orange peppers <span>1.4 mg \/ 100g<\/span><\/li>\r\n <\/ul>\r\n <\/div>\r\n <div class=\"food-card\">\r\n <h4>Omega-3 Sources (EPA+DHA)<\/h4>\r\n <ul>\r\n <li>Mackerel <span>2,600 mg \/ 100g<\/span><\/li>\r\n <li>Salmon (Atlantic) <span>2,260 mg \/ 100g<\/span><\/li>\r\n <li>Sardines (canned) <span>1,480 mg \/ 100g<\/span><\/li>\r\n <li>Anchovies <span>2,100 mg \/ 100g<\/span><\/li>\r\n <li>Herring <span>1,700 mg \/ 100g<\/span><\/li>\r\n <li>Trout <span>1,000 mg \/ 100g<\/span><\/li>\r\n <\/ul>\r\n <\/div>\r\n <div class=\"food-card\">\r\n <h4>Vitamin C Sources<\/h4>\r\n <ul>\r\n <li>Red pepper (raw) <span>190 mg \/ 100g<\/span><\/li>\r\n <li>Guava <span>228 mg \/ 100g<\/span><\/li>\r\n <li>Kiwi <span>93 mg \/ 100g<\/span><\/li>\r\n <li>Broccoli (raw) <span>89 mg \/ 100g<\/span><\/li>\r\n <li>Strawberries <span>59 mg \/ 100g<\/span><\/li>\r\n <li>Orange <span>53 mg \/ 100g<\/span><\/li>\r\n <\/ul>\r\n <\/div>\r\n <div class=\"food-card\">\r\n <h4>Zinc Sources<\/h4>\r\n <ul>\r\n <li>Oysters <span>78 mg \/ 100g<\/span><\/li>\r\n <li>Beef (lean) <span>6 mg \/ 100g<\/span><\/li>\r\n <li>Pumpkin seeds <span>7.8 mg \/ 100g<\/span><\/li>\r\n <li>Cashews <span>5.6 mg \/ 100g<\/span><\/li>\r\n <li>Chickpeas <span>2.8 mg \/ 100g<\/span><\/li>\r\n <li>Lentils <span>3.3 mg \/ 100g<\/span><\/li>\r\n <\/ul>\r\n <\/div>\r\n <\/div>\r\n <p style=\"font-size:0.8rem; color:var(--ink-light);\">* Egg yolk lutein has exceptionally high bioavailability (~3\u00d7 that of vegetables) due to the natural fat matrix. One egg per day provides meaningful lutein despite the lower absolute dose.<\/p>\r\n\r\n <div class=\"callout callout-gold\">\r\n <div class=\"callout-icon\">\r\n <svg viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"1.5\"><path d=\"M12 9v3.75m-9.303 3.376c-.866 1.5.217 3.374 1.948 3.374h14.71c1.73 0 2.813-1.874 1.948-3.374L13.949 3.378c-.866-1.5-3.032-1.5-3.898 0L2.697 16.126zM12 15.75h.007v.008H12v-.008z\"\/><\/svg>\r\n <\/div>\r\n <div class=\"callout-body\">\r\n <strong>Why Food Alone Is Usually Not Enough<\/strong>\r\n <p>The average Western diet provides approximately 1\u20132 mg of lutein per day. The clinical threshold for meaningful macular pigment protection is 10 mg per day. To reach 10 mg from food alone, you would need to eat roughly 2 cups of cooked kale daily \u2014 consistently, for years. Supplementation bridges this gap reliably, which is why the National Eye Institute used supplements rather than dietary counselling in AREDS2.<\/p>\r\n <\/div>\r\n <\/div>\r\n <\/section>\r\n\r\n <!-- MID CTA \u2014 SLOT 1 -->\r\n <div class=\"mid-cta\">\r\n <div class=\"mid-cta-text\">\r\n <strong>Looking for the best AREDS2-based supplement?<\/strong>\r\n <p>See our independently ranked review of the top lutein & zeaxanthin formulas \u2014 from AREDS2 to premium triple carotenoid picks.<\/p>\r\n <\/div>\r\n <a href=\"\/best-lutein-zeaxanthin-supplements\/\" class=\"btn-mid\">See Top Picks \u2192<\/a>\r\n <\/div>\r\n\r\n <!-- SECTION 7: PROTOCOL -->\r\n <div class=\"sec-divider\"><span>Prevention Protocol<\/span><\/div>\r\n <section id=\"protocol\">\r\n <h2>Prevention Protocol by Age Group<\/h2>\r\n <p>Risk accumulates over decades. The appropriate supplementation intensity scales with age, risk profile and current AMD status.<\/p>\r\n\r\n <div class=\"protocol-wrap\">\r\n <table class=\"protocol-table\">\r\n <thead>\r\n <tr>\r\n <th>Profile<\/th>\r\n <th>Recommended Protocol<\/th>\r\n <th>Priority Nutrients<\/th>\r\n <th>Notes<\/th>\r\n <\/tr>\r\n <\/thead>\r\n <tbody>\r\n <tr>\r\n <td>Under 40 \u2014 No risk factors<\/td>\r\n <td>Dietary optimisation + basic supplementation<\/td>\r\n <td>Lutein 10 mg + Omega-3 1,000 mg<\/td>\r\n <td>Build macular pigment early. Focus on Mediterranean diet pattern.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td>40\u201355 \u2014 Screen worker or light iris<\/td>\r\n <td>Preventive supplement stack<\/td>\r\n <td>Lutein 10 mg + Zeaxanthin 2 mg + Astaxanthin 6 mg + Omega-3 1,000 mg<\/td>\r\n <td>Address both blue light and dry eye. Astaxanthin adds fatigue protection.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td>55+ \u2014 No AMD diagnosed<\/td>\r\n <td>AREDS2-adjacent protocol<\/td>\r\n <td>Full AREDS2 formula + Omega-3 2,000 mg + Astaxanthin 12 mg<\/td>\r\n <td>Discuss with ophthalmologist. Annual dilated eye exam essential.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td>Intermediate AMD diagnosed<\/td>\r\n <td>Full AREDS2 formula<\/td>\r\n <td>Lutein 10 mg + Zeaxanthin 2 mg + Vit C 500 mg + Vit E 400 IU + Zinc 80 mg<\/td>\r\n <td>This is the validated protocol. Use PreserVision AREDS2 or equivalent. Monitor copper with high zinc dose.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td>Family history \/ genetic risk (CFH\/ARMS2)<\/td>\r\n <td>Premium triple carotenoid stack<\/td>\r\n <td>Lutein 10 mg + Meso-zeaxanthin 10 mg + Zeaxanthin 2 mg + AREDS2 vitamins<\/td>\r\n <td>Triple carotenoid combination shows greatest MPOD benefit in genetic high-risk groups.<\/td>\r\n <\/tr>\r\n <\/tbody>\r\n <\/table>\r\n <\/div>\r\n\r\n <h3>When to See an Ophthalmologist<\/h3>\r\n <p>Supplements do not replace professional eye care. The following circumstances warrant a prompt dilated eye examination regardless of supplementation status: any sudden change in central vision; new distortion of straight lines (a hallmark early symptom of wet AMD \u2014 test with an Amsler grid); a dark or blurry spot appearing in the central visual field; or any family history of AMD in a first-degree relative. Annual dilated exams are recommended for anyone over 50.<\/p>\r\n <\/section>\r\n\r\n <!-- FINAL CTA \u2014 SLOT 2 -->\r\n <div class=\"final-cta\">\r\n <h2>Start Protecting Your Macula Today<\/h2>\r\n <p>Browse our independently reviewed, ranked picks for the best lutein & zeaxanthin supplements \u2014 from AREDS2-validated formulas to premium triple carotenoid stacks.<\/p>\r\n <div class=\"cta-btn-row\">\r\n <a href=\"\/best-lutein-zeaxanthin-supplements\/\" class=\"btn-gold\">\r\n Best Lutein & Zeaxanthin Picks \u2192\r\n <\/a>\r\n <a href=\"\/best-eye-vitamins-complete-formula\/\" class=\"btn-ghost-light\">\r\n Best Complete Eye Formulas \u2192\r\n <\/a>\r\n <\/div>\r\n <\/div>\r\n\r\n <!-- FAQ -->\r\n <section id=\"faq\">\r\n <h2>Frequently Asked Questions<\/h2>\r\n\r\n <div class=\"faq-item\">\r\n <div class=\"faq-q\" onclick=\"toggleFAQ(this)\">\r\n Can macular degeneration be prevented with supplements?\r\n <svg viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"1.5\"><path d=\"M12 4.5v15m7.5-7.5h-15\"\/><\/svg>\r\n <\/div>\r\n <div class=\"faq-a\">Supplements cannot guarantee prevention, but the AREDS2 study demonstrated that lutein and zeaxanthin significantly reduced the risk of AMD progression in high-risk individuals. For people with no current AMD, these nutrients build the macular pigment that acts as the eye's primary defence against oxidative damage. The epidemiological evidence consistently shows that higher dietary and supplemental lutein\/zeaxanthin intake is associated with significantly lower AMD incidence.<\/div>\r\n <\/div>\r\n\r\n <div class=\"faq-item\">\r\n <div class=\"faq-q\" onclick=\"toggleFAQ(this)\">\r\n What is the AREDS2 formula?\r\n <svg viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"1.5\"><path d=\"M12 4.5v15m7.5-7.5h-15\"\/><\/svg>\r\n <\/div>\r\n <div class=\"faq-a\">The AREDS2 formula is the supplement combination tested in the Age-Related Eye Disease Study 2, conducted by the National Eye Institute. It contains lutein 10 mg, zeaxanthin 2 mg, vitamin C 500 mg, vitamin E 400 IU, zinc 80 mg, and copper 2 mg per day. This combination was shown to reduce the risk of intermediate AMD progressing to advanced AMD by up to 26% over 5 years in the primary trial, with continued benefit confirmed at 10-year follow-up.<\/div>\r\n <\/div>\r\n\r\n <div class=\"faq-item\">\r\n <div class=\"faq-q\" onclick=\"toggleFAQ(this)\">\r\n At what age should I start taking eye supplements for AMD prevention?\r\n <svg viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"1.5\"><path d=\"M12 4.5v15m7.5-7.5h-15\"\/><\/svg>\r\n <\/div>\r\n <div class=\"faq-a\">Macular pigment density begins declining in the 30s and 40s in most people. Starting lutein and zeaxanthin supplementation in your 30s or 40s \u2014 before any symptoms appear \u2014 provides the greatest long-term benefit by building and maintaining the macular pigment that protects against decades of cumulative damage. By the time AMD is diagnosed, significant structural damage has already occurred. Earlier is better.<\/div>\r\n <\/div>\r\n\r\n <div class=\"faq-item\">\r\n <div class=\"faq-q\" onclick=\"toggleFAQ(this)\">\r\n What foods are best for macular degeneration prevention?\r\n <svg viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"1.5\"><path d=\"M12 4.5v15m7.5-7.5h-15\"\/><\/svg>\r\n <\/div>\r\n <div class=\"faq-a\">The highest-value foods are dark leafy greens (kale, spinach, collard greens) for lutein and zeaxanthin; egg yolks for exceptionally bioavailable lutein; fatty fish (salmon, sardines, mackerel) for omega-3s; and orange-yellow vegetables (sweet corn, orange peppers) for zeaxanthin. A Mediterranean dietary pattern overall is consistently associated with lower AMD risk. However, reaching the 10 mg\/day therapeutic dose of lutein from food alone is very difficult for most people, making supplementation important.<\/div>\r\n <\/div>\r\n\r\n <div class=\"faq-item\">\r\n <div class=\"faq-q\" onclick=\"toggleFAQ(this)\">\r\n Is there a difference between dry and wet AMD for supplementation?\r\n <svg viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"1.5\"><path d=\"M12 4.5v15m7.5-7.5h-15\"\/><\/svg>\r\n <\/div>\r\n <div class=\"faq-a\">Yes. The AREDS2 formula was validated for people with intermediate or advanced dry AMD (and those with advanced AMD in one eye). For wet AMD, the primary treatment is anti-VEGF injections administered by an ophthalmologist \u2014 supplements do not treat active neovascular disease. However, supplements may still support the non-affected eye and slow progression in the fellow eye. Anyone with wet AMD should be under active ophthalmological care, with supplements used as adjunctive nutritional support.<\/div>\r\n <\/div>\r\n <\/section>\r\n\r\n <!-- SHARE -->\r\n <div class=\"share-bar\">\r\n <span class=\"share-label\">Share this guide<\/span>\r\n <button class=\"share-btn\" onclick=\"navigator.clipboard.writeText(window.location.href)\">\r\n <svg viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"1.5\" width=\"14\" height=\"14\"><path d=\"M13.19 8.688a4.5 4.5 0 011.242 7.244l-4.5 4.5a4.5 4.5 0 01-6.364-6.364l1.757-1.757m13.35-.622l1.757-1.757a4.5 4.5 0 00-6.364-6.364l-4.5 4.5a4.5 4.5 0 001.242 7.244\"\/><\/svg>\r\n Copy Link\r\n <\/button>\r\n <a class=\"share-btn\" href=\"https:\/\/twitter.com\/intent\/tweet?text=Macular+Degeneration+Prevention%3A+What+the+Science+Says&url=https:\/\/nutra-supplements.com\/macular-degeneration-prevention-supplements\/\" target=\"_blank\" rel=\"noopener\">\r\n <svg viewBox=\"0 0 24 24\" fill=\"currentColor\" width=\"13\" height=\"13\"><path d=\"M18.244 2.25h3.308l-7.227 8.26 8.502 11.24H16.17l-4.714-6.231-5.401 6.231H2.746l7.73-8.835L1.254 2.25H8.08l4.713 6.231zm-1.161 17.52h1.833L7.084 4.126H5.117z\"\/><\/svg>\r\n X \/ Twitter\r\n <\/a>\r\n <a class=\"share-btn\" href=\"https:\/\/www.facebook.com\/sharer\/sharer.php?u=https:\/\/nutra-supplements.com\/macular-degeneration-prevention-supplements\/\" target=\"_blank\" rel=\"noopener\">\r\n <svg viewBox=\"0 0 24 24\" fill=\"currentColor\" width=\"13\" height=\"13\"><path d=\"M24 12.073c0-6.627-5.373-12-12-12s-12 5.373-12 12c0 5.99 4.388 10.954 10.125 11.854v-8.385H7.078v-3.47h3.047V9.43c0-3.007 1.792-4.669 4.533-4.669 1.312 0 2.686.235 2.686.235v2.953H15.83c-1.491 0-1.956.925-1.956 1.874v2.25h3.328l-.532 3.47h-2.796v8.385C19.612 23.027 24 18.062 24 12.073z\"\/><\/svg>\r\n Facebook\r\n <\/a>\r\n <\/div>\r\n\r\n <!-- RELATED -->\r\n <section>\r\n <h2 style=\"margin-bottom:0.5rem;\">Continue in the Vision Health Hub<\/h2>\r\n <p style=\"color:var(--ink-light); font-size:0.9rem; margin-bottom:1.4rem;\">Next articles in the series:<\/p>\r\n <div class=\"related-grid\">\r\n <a href=\"\/best-lutein-zeaxanthin-supplements\/\" class=\"related-card\">\r\n <span class=\"related-type\">Product Review<\/span>\r\n <div class=\"related-title\">Best Lutein & Zeaxanthin Supplements 2026 \u2014 AREDS2 & Premium Picks<\/div>\r\n <\/a>\r\n <a href=\"\/best-eye-vitamins-complete-formula\/\" class=\"related-card\">\r\n <span class=\"related-type\">Product Review<\/span>\r\n <div class=\"related-title\">Best Complete Eye Vitamin Formulas 2026 \u2014 All-in-One Ranked<\/div>\r\n <\/a>\r\n <a href=\"\/top-5-nutrients-protect-vision-blue-light\/\" class=\"related-card\">\r\n <span class=\"related-type\">Science Guide<\/span>\r\n <div class=\"related-title\">Top 5 Nutrients to Protect Your Vision from Blue Light<\/div>\r\n <\/a>\r\n <a href=\"\/category\/vision-health\/\" class=\"related-card\">\r\n <span class=\"related-type\">Hub Index<\/span>\r\n <div class=\"related-title\">\u2190 Back to Vision Health Hub \u2014 All 12 Articles<\/div>\r\n <\/a>\r\n <\/div>\r\n <\/section>\r\n\r\n <\/div>\r\n <\/div>\r\n<\/main>\r\n\r\n<!-- FOOTER -->\r\n<footer>\r\n <div class=\"container\">\r\n <p class=\"footer-disclaimer\">\r\n This website participates in affiliate programs including the Amazon Services LLC Associates Program and other international affiliate networks. We may earn commissions from qualifying purchases at no extra cost to you. All content is for informational purposes only and is not medical advice. Always consult a qualified healthcare professional before starting any supplement regimen.\r\n <\/p>\r\n <nav class=\"footer-links\">\r\n <a href=\"\/affiliate-disclosure\/\">Affiliate Disclosure<\/a>\r\n <a href=\"\/privacy-policy\/\">Privacy Policy<\/a>\r\n <a href=\"\/contact\/\">Contact<\/a>\r\n <\/nav>\r\n <p class=\"footer-copy\">\u00a9 2026 Nutra-Supplements.com \u2013 All Rights Reserved.<\/p>\r\n <\/div>\r\n<\/footer>\r\n\r\n<script>\r\nfunction toggleFAQ(el) {\r\n el.classList.toggle('open');\r\n el.nextElementSibling.classList.toggle('visible');\r\n}\r\nwindow.addEventListener('scroll', () => {\r\n const d = document.documentElement;\r\n document.getElementById('progress').style.width = (d.scrollTop \/ (d.scrollHeight - d.clientHeight) * 100) + '%';\r\n});\r\n<\/script>\r\n<\/body>\r\n<\/html>\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Macular Degeneration Prevention: What the Science Says (2026) | Nutra Supplements Vision Health Complete Guide Home EN ES DE FR IT Home Vision Health Macular Degeneration Prevention: What the Science Says Science Guide \u00b7 Vision Health Macular Degeneration Prevention: What the Science Says (2026) April 12, 2026 12 min read AREDS2 \u00b7 Peer-reviewed \u00b7 ~3,600 … <a title=\"Macular Degeneration Prevention: What the Science Says (2026)\" class=\"read-more\" href=\"https:\/\/nutra-supplements.com\/fr\/macular-degeneration-prevention-supplements\/\" aria-label=\"Read more about Macular Degeneration Prevention: What the Science Says (2026)\">Lire la suite<\/a><\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"elementor_canvas","format":"standard","meta":{"footnotes":""},"categories":[21],"tags":[],"class_list":["post-368","post","type-post","status-publish","format-standard","hentry","category-vision-health"],"_links":{"self":[{"href":"https:\/\/nutra-supplements.com\/fr\/wp-json\/wp\/v2\/posts\/368","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nutra-supplements.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nutra-supplements.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nutra-supplements.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nutra-supplements.com\/fr\/wp-json\/wp\/v2\/comments?post=368"}],"version-history":[{"count":4,"href":"https:\/\/nutra-supplements.com\/fr\/wp-json\/wp\/v2\/posts\/368\/revisions"}],"predecessor-version":[{"id":373,"href":"https:\/\/nutra-supplements.com\/fr\/wp-json\/wp\/v2\/posts\/368\/revisions\/373"}],"wp:attachment":[{"href":"https:\/\/nutra-supplements.com\/fr\/wp-json\/wp\/v2\/media?parent=368"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nutra-supplements.com\/fr\/wp-json\/wp\/v2\/categories?post=368"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nutra-supplements.com\/fr\/wp-json\/wp\/v2\/tags?post=368"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}